ISU Abxis Co., Ltd. (KOSDAQ:086890)

Market Cap	230.08B
Revenue (ttm)	59.42B
Net Income (ttm)	29.52B
Shares Out	39.67M
EPS (ttm)	672.86
PE Ratio	8.62
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,958,321
Average Volume	614,042
Open	5,250.00
Previous Close	5,260.00
Day's Range	5,220.00 - 5,950.00
52-Week Range	3,945.00 - 6,180.00
Beta	0.49
RSI	59.12
Earnings Date	Aug 8, 2025

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 178
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086890

Financial Performance

In 2024, ISU Abxis's revenue was 60.26 billion, an increase of 10.96% compared to the previous year's 54.31 billion. Earnings were 14.72 billion, an increase of 307.63%.